Medical Oncologist
Medicines
How does pertuzumab work, and who is it for?
Pertuzumab is an antibody that stops the HER2 protein pairing with its partners, cutting off strong growth signals in HER2-positive breast cancer. Given with trastuzumab, which blocks HER2 at a different site, it provides fuller blockade. This page explains, in general terms, how it works, how HER2 is tested and who it is usually considered for.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed September 2026, next review due September 2027
On this page
- How does pertuzumab work, and who is it for?
- Four ways dual HER2 blockade works
- Is pertuzumab usually considered?
- The vocabulary, in plain language
- Honest realities about how pertuzumab works
- How HER2 status is confirmed
- Why pertuzumab is often given before surgery
- What people assume about how pertuzumab works
- Common questions about how pertuzumab works
The short answer
How does pertuzumab work, and who is it for?
About one in five breast cancers make too much of a protein called HER2, which sits on the surface of cells and acts like an antenna for growth signals. When there is far too much HER2, the cancer cells receive a constant message to grow and divide, which is why HER2-positive cancers tended to be aggressive before targeted treatments existed. HER2 rarely works alone. To send its strongest signals, it pairs up with partner proteins, especially one called HER3. Pertuzumab is an antibody, a laboratory-made protein designed to attach to one specific target. It locks onto the part of HER2 that it uses to pair with its partners, and so stops those pairs from forming. Trastuzumab, the older HER2 antibody, attaches to a different part of HER2 and blocks signalling in a different way. Both antibodies also flag cancer cells to the immune system, which can then attack them. Using the two together blocks HER2 more completely than either alone, which is why pertuzumab is always given with trastuzumab. Pertuzumab is for people whose cancer is confirmed as HER2-positive on biopsy testing. It is mainly used in early cancers with a higher risk of returning, such as those that are larger or have reached lymph nodes, especially before surgery, and in advanced HER2-positive cancer as a first treatment. It is not used for HER2-negative or HER2-low cancers, which are treated differently.
It blocks HER2 pairing
By stopping HER2 joining its partners, pertuzumab cuts off one of the strongest growth signals in these cancers.
It complements trastuzumab
The two antibodies attach at different sites, so together they give a fuller blockade.
A positive HER2 test is essential
Without clear HER2 positivity, pertuzumab is not expected to help.
This page gives general information only. Your oncologist will explain what your own HER2 result means.How it acts
Four ways dual HER2 blockade works
The combination attacks HER2-driven growth from several directions at once.
Stopping partnerships
Pertuzumab prevents HER2 from pairing with HER3 and related proteins, silencing a powerful growth signal.
Blocking HER2 directly
Trastuzumab attaches to another part of HER2 and reduces signalling from HER2 itself.
Different sites mean they do not compete.Calling in the immune system
Both antibodies act as flags that help immune cells recognise and attack cancer cells.
Working with chemotherapy
Chemotherapy damages dividing cells while the antibodies cut growth signals, making the combination more effective.
Often given with
- Docetaxel or paclitaxel
- Carboplatin
- Hormone therapy later, if also hormone positive
Who it suits
Is pertuzumab usually considered?
Situation
General position
HER2-positive, larger or node-positive, before surgery
Commonly considered
HER2-positive, node-positive, after surgery
Often considered
HER2-positive, small and node-negative
Usually not needed; benefit is small
HER2-positive advanced cancer, first treatment
Standard option with trastuzumab and chemotherapy
HER2-low or HER2-negative
Not used
Words you will hear
The vocabulary, in plain language
- HER2
- A growth signal protein on the surface of some cells.
- Monoclonal antibody
- A laboratory-made protein designed to attach to one specific target.
- Dimerisation
- Two proteins pairing up to send a signal; pertuzumab blocks this for HER2.
- Immunohistochemistry
- A staining test on biopsy tissue that scores how much HER2 is present.
- ISH test
- A test that counts copies of the HER2 gene, used when staining is borderline.
- HER2-low
- Some HER2 present but not enough to count as positive; treated differently.
Talk to our team
Have a question about your situation?
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Being straight with you
Honest realities about how pertuzumab works
A clear scientific idea does not always translate into large benefit for every person.
More blockade is not always much more benefit
In lower-risk early cancer, trastuzumab and chemotherapy already work very well, leaving less room for pertuzumab to add.
Resistance can develop
In advanced cancer, cancer cells can find other routes to grow, and treatment eventually needs to change.
Testing quality matters
An inaccurate HER2 result could lead to the wrong treatment, which is why borderline results are rechecked.
Two antibodies, two different targets
Pertuzumab and trastuzumab attach to different parts of the HER2 receptor, so they do not compete with each other. That is why they can be given together, but it also means both add their own possible side effects, especially loose motions.
What this page cannot tell you
It cannot interpret your HER2 report. Your oncologist and pathologist can.
Finding out
How HER2 status is confirmed
Every newly diagnosed invasive breast cancer should be tested for HER2, usually on the biopsy sample.
Staining test first
The immunohistochemistry test scores HER2 on a scale from zero to three. The highest score means HER2-positive.
Gene test for borderline results
A middle score needs an ISH test, which counts HER2 gene copies to settle whether the cancer is positive.
Retesting in some cases
If cancer returns or spreads, a new biopsy may be tested again, because HER2 status can occasionally change.
Where the test is done matters
HER2 results are most reliable when the laboratory handles the tissue promptly, follows standard scoring guidance and takes part in regular quality checks. If your report came from a small laboratory and the result is borderline, your oncologist may ask for the sample to be reviewed again before a decision about pertuzumab is made.
Ask for your report
Keep a copy of your receptor and HER2 results; every future doctor will need them.
Timing
Why pertuzumab is often given before surgery
Starting HER2 treatment before surgery has become common for larger or node-positive HER2-positive cancers.
Seeing the response
Surgery shows how completely the treatment worked. No invasive cancer left behind is a very good sign.
Guiding treatment after surgery
If some cancer remains, treatment is usually switched to trastuzumab emtansine, which lowers the risk of recurrence in that situation.
Possibly smaller surgery
Shrinking the cancer first can sometimes allow breast-conserving surgery instead of a mastectomy.
Commonly believed
What people assume about how pertuzumab works
HER2-positive means the worst kind of breast cancer.
With targeted treatment, outcomes for many HER2-positive cancers are now good.
Pertuzumab and trastuzumab do the same job.
They attach to different parts of HER2 and block different signals.
It can help any breast cancer.
It only helps cancers that are clearly HER2-positive.
Antibodies weaken my immune system.
These antibodies help immune cells find cancer; low counts come from chemotherapy.
Questions we are asked
Common questions about how pertuzumab works
Why can pertuzumab not be given alone?
On its own, pertuzumab has shown limited activity. Its strength comes from complementing trastuzumab, blocking a different part of HER2 signalling. The trials that proved its benefit all used the two antibodies together, usually with chemotherapy, so that is how it is prescribed.
What does HER2-positive mean on my report?
It means your cancer cells have high levels of HER2, shown by the highest score on the staining test or by extra copies of the HER2 gene. This result makes you eligible for HER2-targeted medicines such as trastuzumab and pertuzumab.
My cancer is hormone positive and HER2-positive. What changes?
You will usually receive HER2-targeted treatment, often including pertuzumab if the risk is higher, and hormone therapy as well. Hormone therapy typically starts after chemotherapy and can be given at the same time as the antibodies.
Does pertuzumab reach the brain?
Large antibodies do not cross into the brain easily. Brain spread in HER2-positive cancer is often treated with surgery, radiotherapy or HER2-targeted tablets that reach the brain better. Your team will explain the options if this is relevant.
How quickly does it start working?
Antibodies begin attaching to HER2 soon after the first dose. When given before surgery with chemotherapy, many cancers shrink noticeably within the first few cycles, although your team judges response with examinations and scans.
Can HER2 status change over time?
Occasionally, yes. That is why a new biopsy is often recommended if cancer returns or spreads. A change can alter which treatments are suitable, so retesting gives your team the most accurate picture.
Is pertuzumab used for HER2-low cancer?
No. HER2-low cancers do not respond to pertuzumab and trastuzumab in the same way. In advanced HER2-low cancer, a different medicine called trastuzumab deruxtecan may be considered instead.
What happens if the cancer stops responding?
In advanced cancer, your oncologist will move to other HER2-targeted options, such as antibody-drug conjugates or HER2-targeted tablets with chemotherapy. HER2 remains a useful target even after pertuzumab stops working.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Where to find us
Our centres in and around Hyderabad
Addressed by landmark, because that is how this city navigates. Each centre also names the areas it serves, so you can place it without a map. Consultation and day-care Chemotherapy run at every one of them.
Warangal
Vizag
Talk to our team
Speak to a breast cancer specialist
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Sources
- National Cancer Institute — Pertuzumab
- American Cancer Society — Targeted drug therapy for breast cancer
- Breast Cancer Now — HER2 status and breast cancer
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.